Journal article
Ursodeoxycholic Acid Improves Cholestasis in Infants with Cystic Fibrosis
The Annals of pharmacotherapy, Vol.31(9), pp.1003-1005
09/1997
DOI: 10.1177/106002809703100909
PMID: 9296240
Abstract
Objective: To describe two infants with cholestatic jaundice treated with ursodeoxycholic acid (UDCA).
Case summary: Two infants with cystic fibrosis (CF)-associated hepatobiliary disease, manifesting as cholestatic jaundice and elevated liver enzymes within the first 6 weeks of life, had improved biochemical indices of liver function following treatment with UDCA 20-40 mg/kg/d.
Discussion: To our knowledge, this is the first report of UDCA treatment in infants with CF-associated cholestatic jaundice. Infants and children require treatment with increased doses of UDCA to compensate for reduced intestinal absorption of bile acid and immaturity of the enterohepatic circulation.
Conclusions: UDCA appears to be a cost-effective treatment for CF-associated hepatobiliary disease in infants and children.
Details
- Title: Subtitle
- Ursodeoxycholic Acid Improves Cholestasis in Infants with Cystic Fibrosis
- Creators
- Herschel Scher - Pediatric Allergy/Pulmonary Division, Department of Pediatrics, College of Medicine, University of Iowa, Iowa City, IAWarren P Bishop - Pediatric Gastroenterology Division, Department of Pediatrics, College of Medicine, University of IowaPaul B Mccray - Pediatric Allergy/Pulmonary Division, Department of Pediatrics, College of Medicine, University of Iowa
- Resource Type
- Journal article
- Publication Details
- The Annals of pharmacotherapy, Vol.31(9), pp.1003-1005
- DOI
- 10.1177/106002809703100909
- PMID
- 9296240
- ISSN
- 1060-0280
- eISSN
- 1542-6270
- Language
- English
- Date published
- 09/1997
- Academic Unit
- Microbiology and Immunology; Pulmonary Medicine; Stead Family Department of Pediatrics; Internal Medicine
- Record Identifier
- 9984093482202771
Metrics
16 Record Views